Stocks finished higher Tuesday as solid earnings reports outweighed jitters about the spread of COVID-19's delta variant and China's clampdown on its gaming and technology sectors.
Here are some of the market's biggest gainers for Tuesday:
1. Under Armour | Increase 7.6%
Under Armour (UAA) - Get Under Armour, Inc. Class A Report shares spiked after the sports-apparel company posted stronger-than-expected second-quarter earnings and boosted its 2021 sales forecast. Revenue rose 91% to $1.4 billion, topping the consensus analyst estimate of $1.2 billion.
2. ZoomInfo Technologies | Increase 3.1%
ZoomInfo Technologies (ZI) - Get ZoomInfo Technologies Report shares climbed after the cloud-based data platform for sales-and-marketing applications beat Wall Street's second-quarter-earnings expectations. Earnings doubled to 14 cents a share, beating the Zacks consensus estimate of 12 cents. Revenue totaled $174 million, up 57% from a year earlier.
3. Translate Bio | Increase 29%
Shares of Translate Bio (TBIO) - Get Translate Bio, Inc. Report surged after French drugmaker Sanofi (SNY) - Get Sanofi Sponsored ADR Report agreed to buy its messenger-RNA development partner for $3.2 billion cash. Sanofi said it would pay $38 for each of Translate Bio’s shares. The transaction has been approved by the boards of both companies.
4. Outlook Therapeutics | Increase 6.6%
Outlook Therapeutics (OTLK) - Get Outlook Therapeutics, Inc. Report shares climbed after the biopharmaceutical company reported positive results for its treatment of neovascular age-related macular degeneration, or wet AMD, ONS-5010/Lytenava. The trial enrolled a total of 228 subjects with wet AMD across 39 clinical trial sites in the U.S.
5. Arcturus Therapeutics | Increase 68%
Shares of Arcturus Therapeutics (ARCT) - Get Arcturus Therapeutics Holdings, Inc. Report surged after the biotech said the Singapore Health Sciences Authority approved the advancement of two messenger RNA COVID-19 vaccine candidates into Phase 1/2 clinical testing.